MDMB-CHMINACA

MDMB-CHMINACA^[1] (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB₁ receptor,^[2] and has been sold online as a designer drug.^{[3][4][5][6][7]} It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB₁, and an EC₅₀ of 0.330 nM.^[8] It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.^[9]

MDMB-CHMINACA

Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B Illegal in Singapore and Switzerland
Identifiers
IUPAC name Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazol-3-yl]formamido}-3,3-dimethylbutanoate
CAS Number	1185888-32-7
PubChem CID	121491808
ChemSpider	32055574
UNII	Z6EXBVG316
CompTox Dashboard (EPA)	DTXSID001010034
Chemical and physical data
Formula	C22H31N3O3
Molar mass	385.508 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3
InChI InChI=1S/C22H31N3O3/c1-22(2,3)19(21(27)28-4)23-20(26)18-16-12-8-9-13-17(16)25(24-18)14-15-10-6-5-7-11-15/h8-9,12-13,15,19H,5-7,10-11,14H2,1-4H3,(H,23,26)/t19-/m1/s1 Key:DGQMLBSSRFFINY-LJQANCHMSA-N

Legal status

MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015.^[10]

MDMB-CHMINACA is illegal in Germany, Switzerland as of December 2015.^[11]

Sweden's public health agency suggested classifying MDMB-CHMINACA as a hazardous substance, on September 25, 2019.^[12]

See also

• AB-CHMINACA
• ADB-CHMINACA
• ADB-FUBINACA
• MDMB-CHMICA
• MDMB-FUBINACA
• PX-3 (APP-CHMINACA)